Avalo Therapeutics
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
Revenue | $59 | $0 | $0 | $0 |
Gross Profit | 43 | 0 | -134 | 0 |
EBITDA | -19,726 | -30,555 | -19,182 | -14,534 |
EBIT | -19,742 | -30,614 | -19,316 | -14,669 |
Net Income | -13,720 | -30,625 | -20,765 | -13,149 |
Net Change In Cash | 59 | 0 | 0 | 0 |
Free Cash Flow | -14,246 | -16,365 | -11,390 | -9,457 |
Cash | 15,858 | 26,963 | 42,290 | 125,046 |
Basic Shares | 13,404 | 14,000 | 10,829 | 10,514 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $59 | $441 | $1,924 | $18,051 |
Gross Profit | -285 | 807 | 640 | 14,617 |
EBITDA | -72,925 | -68,343 | -23,286 | -37,274 |
EBIT | -73,269 | -68,512 | -23,444 | -37,440 |
Net Income | -78,259 | -35,129 | -31,544 | -41,658 |
Net Change In Cash | 59 | 441 | 1,924 | 18,051 |
Free Cash Flow | -51,458 | -49,056 | -30,838 | -26,846 |
Cash | 15,858 | 134,546 | 7,415 | 13,172 |
Basic Shares | 13,404 | 10,784 | 277 | 39 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-12-31 | -$0.37 |
2025-09-30 | -$2.19 |
2025-06-30 | -$1.92 |
2025-03-31 | -$1.28 |
